第一三共株式会社

October is Breast Cancer Awareness Month, and in honor of the month’s iconic symbol, the “Pink Ribbon,” Daiichi Sankyo's Shinagawa R&D Center in Tokyo is illuminated in pink from 5:00 PM to 10:00 PM until October 31st. In the photo, both Mitake Bridge in front of the Center and the Shinagawa R&D Center itself are illuminated in pink, creating a magical “pink collaboration.” Tokyo’s Shinagawa Ward, where the R&D center is located, also participated in a similar initiative, lighting up 13 bridges within the ward for one day on October 1st.

On July 9th, the new “Daiichi Sankyo Straße” in #Pfaffenhofen was officially inaugurated. At the ceremony, Head of Plant Management Matthias Kühn and Nora Urbanetz, Head of Technology Unit Europe, welcomed the guests of honor: Roland Doerfler, Second Mayor of Pfaffenhofen, and Hiroto Kashiwase, Global Head of Technology Unit at Daiichi Sankyo, who was accompanied by members of the global Technology Unit team. Together, they unveiled the newly named street sign in front of the plant entrance. “This event is more than just a ceremony,” said Matthias Kühn. “It’s a strong symbol of the deep roots our company has developed here – and of the long-standing, trusted partnership with the city of Pfaffenhofen.” Hiroto Kashiwase added: “I would like to thank all our colleagues in Pfaffenhofen for their outstanding contribution to Daiichi Sankyo’s global success. I also want to thank the city of Pfaffenhofen for its ongoing partnership – creating an environment where industry, science, and community can grow together sustainably.” Nora Urbanetz emphasised the future role of the site: “Our site in Pfaffenhofen plays an increasingly important role in fulfilling our company’s mission to develop innovative medicines and supply patients around the world. We’re committed to continuing that journey – and to growing further in the years ahead.” 💚 Matthias Kuehn, NORA URBANETZ, Kashiwase Hiroto #DaiichiSankyoEurope

Dr. Yuki Abe, Corporate Officer and Head of Research at Daiichi Sankyo is a visionary leader driving innovation in drug discovery and oncology through cross-disciplinary teamwork. Dr. Abe believes, “To create truly outstanding medicines, it’s crucial to build an environment where each individual can fully demonstrate their capabilities.” His journey from a young researcher to leading global teams is a testament to the power of collaboration and expertise. 🔗 Click on the link to learn more about Dr. Abe and how he is helping to bring innovation to patients at Daiichi Sankyo: https://lnkd.in/gwH4pMn2

On World Cleanup Day this past weekend, over 190 countries joined forces to protect the planet through coordinated environmental efforts. This global movement began in 2008 when young people in Estonia removed over 10,000 tons of illegal waste in a single day, inspiring worldwide participation.     Continuing this commitment in our home country, Japan, Daiichi Sankyo’s Kyushu Pharma Sales Department recently participated in the Love Earth Cleanup 2025 for the third consecutive year. Seventeen employees and family members gathered at Fukuoka’s Seaside Momochi Beach Park to collect and sort various litter, including plastic bottles, cans, and glass.     Such community engagement highlights the importance of proper waste separation to transform trash into valuable resources. It also emphasizes how individual responsibility contributes to addressing marine pollution and advancing sustainability goals.    🔗 Click to learn more about Daiichi Sankyo’s environmental initiatives and the importance of collective action for a cleaner Earth: https://lnkd.in/gGkHFqeu 

What does Patient Safety mean to us at Daiichi Sankyo?

September marks International Childhood Cancer Awareness Month, highlighting that cancer is not only an adult disease and spotlighting the 400,000 children diagnosed annually worldwide. According to the World Health Organization, leukemia, brain tumors, and lymphomas are the most common childhood cancers, and while over 80% survive in high-income countries, survival drops below 30% in low- and middle-income regions due to limited access to care. The gold ribbon is the worldwide symbol of childhood cancer awareness and symbolizes the value of children’s lives, and events nationwide promote awareness and support. We encourage everyone to use the opportunity of childhood cancer awareness month to learn about more childhood cancer as a first step toward greater understanding and action.

On August 31, a strong earthquake occurred in eastern Afghanistan, near the city of Jalalabad. We are saddened by the resulting loss of life and injuries and wish to express our heartfelt condolences to all the persons who have been affected by this disaster.  Daiichi Sankyo has pledged 5,000,000 yen for emergency humanitarian assistance through the Non-Profit Organization, Japan Platform’s “Emergency Response to Eastern Afghanistan Earthquake 2025" initiatives. We hope that this support will help deliver immediate relief to those in need and aid them in their journey towards a peaceful recovery. 🔗 https://lnkd.in/gGcWVczM

Norihito Kawasaki has been with Daiichi Sankyo since August 2017, focusing on patient-centric oncology research in the pursuit of innovative medicine discovery. As the lead of the pharmacology research team, Norihito aims to develop next-generation anti-cancer medicines, recognizing the importance of an environment that encourages experimentation and learning from both success and failure, ensuring that innovative ideas become effective medicines. 🔗 Click to learn more about how Norihito is shaping the future of medicine at Daiichi Sankyo: https://lnkd.in/ggAT337m

Daiichi Sankyo in Japan has been selected as a “Digital Transformation Stocks (DX Stocks) 2025.” DX Stocks is a program to select outstanding companies listed on Tokyo Stock Exchange by the Japanese Ministry of Economy, Trade and Industry (METI), the Tokyo Stock Exchange (TSE), and the Information-technology Promotion Agency of Japan (IPA). Companies selected as DX Stocks have internally established systems for promoting DX, an approach that contributes to improving corporate value, and have achieved outstanding utilization of digital technologies. Through this third consecutive selection, METI, the TSE, and the IPA encourage business executives to improve their awareness of DX by widely publicizing successful companies as role models for other companies, while further promoting DX by helping companies to receive evaluation from a wide variety of stakeholders. 🔗 Click to earn more about this selection: https://lnkd.in/eaEH4hps

We are honored to announce the appointment of Ken Keller to our global Daiichi Sankyo Company, Limited Board of Directors. Ken currently serves as Chairman of the Board, President and CEO of Daiichi Sankyo, Inc. in the United States, and Global Head of the Daiichi Sankyo Oncology Business. His appointment marks a significant milestone as the first U.S. based executive to hold a seat on the Board for Daiichi Sankyo Company, Limited.   With an extensive track record of leadership in the pharmaceutical and oncology sectors, Ken has brought deep strategic insight to help lead the company in its transition into a global oncology company. Congratulations and thank you to all our global leaders, who will undoubtedly drive the Daiichi Sankyo 2030 vision of becoming an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society” forward and help make an even greater impact on the patients of tomorrow.   Appointments effective June 23rd, the Representative Directors and appointees to our Directors and Audit & Supervisory Board Members for Daiichi Sankyo are recognized on our global leadership page here: 🔗https://bit.ly/466YyV7